How China Plans to 'Firmly Rank at the Global Forefront' with 25% of First in Class Drugs The pharmaceutical industry has long been dominated by Western economies, with giants like Pfizer and Merck leading the way.
But as China unveils its latest five year plan to become a biopharmaceutical powerhouse by 2030, it's clear that this is more than just another state driven initiative.
The country aims to "firmly rank at the global forefront" with 25% of first in class drugs, sparking both excitement and trepidation.